p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicenter trial

JAMA

Volumn 277, Issue 19, 1997, Pages 1531-1538

  Abraham, Edward ^a   Glauser, Michel P ^b   Butler, Thomas ^c   Garbino, Jorge ^d   Gelmont, David ^e   Laterre, Pierre F ^f   Kudsk, Kenneth ^g   Bruining, Hajo A ^h   Otto, Charles ⁱ   Tobin, Ellis ^j   Zwingelstein, Christian ^k   Lesslauer, Werner ^k   Leighton, Anton ^k  

^a UNIVERSITY OF COLORADO   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF ARIZONA   (United States)

^j Albany Medical Center   (New Zealand)

^k F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 6; RECEPTOR PROTEIN; TUMOR NECROSIS FACTOR;

ARTICLE; BLOOD LEVEL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME;

EID: 8244235133     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.19.1531     Document Type: Article

References (36)

1. Wenzel RP. Anti-endotoxin monoclonal antibodies: a second look. N Engl J Med. 1992;326:1151-1153.
2. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans. Ann Intern Med. 1990;113:227-242.
3. Young LS. Gram-negative sepsis. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases. 3rd ed. New York, NY: Churchill Livingstone Inc; 1990:611-636.
4. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
5. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987; 317:659-665.
6. Ispahani P, Pearson NJ, Greenwood D. An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom. Q J Med. 1987;63:427-440.
7. The HA-1A Sepsis Study Group. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med. 1991;324:429-436.
8. Parrillo JE. Management of septic shock: present and future. Ann Intern Med. 1991;115:491-493.
9. Bone RC, Fisher CJ Jr, Clemmer TP, et al. Sepsis syndrome. Crit Care Med. 1989;17:389-393.
10. Selby P, Hobbs S, Viner C, et al. Tumor necrosis factor in man. Br J Cancer. 1987;56:803-808.
11. Sherman ML, Spriggs DR, Arthur KA, et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients. J Clin Oncol. 1988;6:344-350.
12. Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of recombinant tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987;5:1942-1951.
13. Van der Poll T, Buller HR, ten Gate HT. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 1990;322:1622-1627.
14. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318: 1481-1486.
15. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating IL-1 and TNF in septic shock and experimental endotoxin fever. J Infect Dis. 1990;161:79-84.
16. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330: 662-664.
17. Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/TNF reduce interleukin-1 and interleukin-6 appearance during lethal bacteremia. J Exp Med. 1989;170:1627-1633.
18. Opal SM, Cross AS, Kelly NM, et al. Efficacy of a monoclonal antibody directed against TNF in protecting neutropenic rats from lethal infection with P aeruginosa. J Infect Dis. 1990;161:1148-1152.
19. Hinshaw LB, Tekamp-Olson P, Chang AC, et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF). Circ Shock. 1990;30:279-292.
20. Hinshaw LB, Emerson TE Jr, Taylor FB Jr, et al. Lethal S aureus shock in primates: prevention of death with anti-TNF antibody. J Trauma. 1992;33: 568-573.
21. Abraham E, Wunderink R, Silverman H, et al, for the TNF-Alpha MAb Sepsis Study Group. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 1995;273:934-941.
22. Lesslauer W, Tabuchi H, Gentz R, et al. Recombinant soluble tumor necrosis factor receptor proteins protect from lipopolysaccharide-induced lethality. Eur J Immunol. 1991;21:2883-2886.
23. Ashkenazi A, Marsters SA, Capon DJ. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A. 1991;88:10535-10539.
24. Higuch M, Aggarwal BB. Inhibition of ligand binding and antiproliferative effects of tumor necrosis factor and lymphotoxin by soluble forms of recombinant P60 and P80 receptors. Biochem Biophys Res Commun. 1992;182:638-643.
25. Peppel K, Crawford D, Beutler B. Tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med. 1991;174:1483-1489.
26. Van Zee KJ, Moldawer LL, Oldenburg HSA, et al. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol. 1996;156:2221-2230.
27. Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med. 1994;180:2173-2179.
28. Knaus WA, Harrell FE, Fisher CJ Jr, et al. The clinical evaluation of new drugs for sepsis. JAMA 1993;270:1233-1241.
29. Hebert PC, Drummond AJ, Singer J, Bernard GR, Russell JA. A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest. 1993;104:230-235.
30. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med. 1996;24:1431-1440.
31. Fisher CJ Jr, Agosti JM, Opal SM, et al, for the Soluble TNF Receptor Sepsis Study Group. Treatment of septic shock with the tumor necrosis factor receptor Fc fusion protein. N Engl J Med. 1996;334: 1697-1702.
32. Suffredni AF, Reda D, Banks SM, et al. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol. 1995;155:5038-5045.
33. Havell EA. Evidence that TNF has an important role in antibacterial resistance. J Immunol. 1989; 143:2894-2899.
34. Goldie AS, Fearon KCH, Ross JA, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA. 1995; 274:172-177.
35. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993;119:771-778.
36. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock. Crit Care Med. 1996;24:733-742.